Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Operating Leases (2019 - 2025)

Historic Operating Leases for Ocular Therapeutix (OCUL) over the last 7 years, with Q4 2025 value amounting to $2.8 million.

  • Ocular Therapeutix's Operating Leases fell 4733.4% to $2.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.8 million, marking a year-over-year decrease of 4733.4%. This contributed to the annual value of $2.8 million for FY2025, which is 4733.4% down from last year.
  • As of Q4 2025, Ocular Therapeutix's Operating Leases stood at $2.8 million, which was down 4733.4% from $3.6 million recorded in Q3 2025.
  • In the past 5 years, Ocular Therapeutix's Operating Leases ranged from a high of $8.7 million in Q4 2022 and a low of $2.8 million during Q4 2025
  • Moreover, its 5-year median value for Operating Leases was $6.0 million (2021), whereas its average is $6.0 million.
  • Its Operating Leases has fluctuated over the past 5 years, first surged by 5728.85% in 2023, then tumbled by 4733.4% in 2025.
  • Ocular Therapeutix's Operating Leases (Quarter) stood at $5.9 million in 2021, then skyrocketed by 46.49% to $8.7 million in 2022, then fell by 20.74% to $6.9 million in 2023, then fell by 22.29% to $5.3 million in 2024, then crashed by 47.33% to $2.8 million in 2025.
  • Its Operating Leases stands at $2.8 million for Q4 2025, versus $3.6 million for Q3 2025 and $4.4 million for Q2 2025.